Metropolis Healthcare Limited has announced the key business parameters of the Company for the quarter ended September 30, 2020:
The Company has achieved highest ever Quarterly Revenue in Q2FY21. The Revenue for Q2FY21 has nearly doubled from Q1FY21 and has grown by ~25% from Q2FY20 levels. In September 2020, revenue growth stood at ~40% as compared to September 2019.
The No. of Patient Visits for Q2FY21 stood at approximately 2.41mn compared to 1.37mn in Q1FY21 and 2.66mn in Q2FY20.
The No. of tests for Q2FY21 stood at approximately 4.35mn compared to 2.65mn in Q1FY21 and 5.17mn in Q2FY20.
The Company has reached ~85% of last year levels in Q2FY21 for Non-Covid business and in comparison to 71% in Q1FY21. In September 2020, the Company has achieved normalcy in nonCovid business compared to September 2019.
With scale-up of Non-Covid business, sustained cost management measures as well as operating leverage on-account of significant uptick in Revenue, the EBITDA margins in Q2FY21 has improved over Q2FY20.
The Company continues to be a net cash company with Cash and Cash equivalents of approximately Rs. 300 Crore at the end of September 30, 2020
The above information is on a Consolidated basis and subject to a limited review by the Management Team.